Bill
A 5562
Bill A 5562 protects epilepsy patients by requiring pharmacists to obtain consent from both prescribers and patients before substituting anti-epileptic medications.
Bill Number: A 5562
Title: Prohibits a pharmacist from substituting any anti-epileptic drug for a prescribed anti-epileptic drug without the informed consent of the prescriber and patient
Status: Referred to Higher Education
Introduced: February 14, 2025
Classification: Bill
Bill A 5562 aims to enhance patient safety and ensure the efficacy of anti-epileptic treatments by prohibiting pharmacists from substituting prescribed anti-epileptic medications without obtaining informed consent from both the prescriber and the patient. This legislation seeks to address concerns regarding the potential risks associated with medication substitutions, particularly for individuals with epilepsy who rely on specific medications for seizure control.
Informed Consent Requirement: The bill mandates that pharmacists must obtain explicit informed consent from both the prescribing healthcare provider and the patient before substituting any anti-epileptic drug.
Definition of Anti-Epileptic Drugs: The legislation specifies that it applies to all medications classified as anti-epileptic, ensuring clarity on which drugs are covered under this requirement.
Exceptions: The bill does not outline specific exceptions, indicating that all substitutions are subject to the informed consent rule.
Patients with Epilepsy: Individuals who are prescribed anti-epileptic drugs will benefit from this bill as it aims to ensure they receive the exact medication intended by their healthcare provider.
Healthcare Providers: Prescribers will have a more significant role in the medication management process, as their consent will be necessary for any substitutions.
Pharmacists: Pharmacists will need to adjust their practices to comply with the new requirement, which may involve additional communication with both prescribers and patients.
Current Status: As of February 14, 2025, the bill has been referred to the Higher Education committee for further consideration.
Legislative History: Bill A 5562 is related to several prior-session bills (A 6574, A 3528, A 9303, A 2991, A 3062, A 3719, A 3982, A 1982, A 635), indicating ongoing legislative interest in the regulation of anti-epileptic drug substitutions.
Bill A 5562 represents a significant step towards protecting patients with epilepsy by ensuring that their prescribed medications are not substituted without proper consent. By reinforcing the roles of both healthcare providers and patients in the medication process, the bill aims to enhance treatment safety and efficacy for those affected by epilepsy. Further developments will be monitored as the bill progresses through the legislative process.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
